A preliminary study of the dopamine DA1 agonist fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease.
The effects of chronic oral fenoldopam in the treatment of NYHA grade II-III heart failure secondary to ischaemic heart disease, were studied in a placebo controlled, double blind, randomised, parallel group fashion in 20 patients. Nine patients taking placebo and six taking fenoldopam completed the study. Adverse events were similar in each group. There were no significant changes in exercise capacity, ejection fraction, body weight or symptom questionnaires with either treatment. This preliminary study has not revealed any benefit of fenoldopam in heart failure due to ischaemic heart disease.
MacDonald
T M
TM
Department of Medicine and Therapeutics, Aberdeen University, Foresterhill.
Jeffrey
R F
RF
Muir
A L
AL
Lee
M R
MR
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D001835:Body Weight / Q000187:drug effects; D003327:Coronary Disease / Q000150:complications*; D015259:Dopamine Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005080:Exercise Test; D018818:Fenoldopam; D006333:Heart Failure / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D006352:Heart Ventricles; D006801:Humans; D008875:Middle Aged; D015635:Radionuclide Ventriculography; D016032:Randomized Controlled Trials as Topic; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology
D015259:Dopamine Agents; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D018818:Fenoldopam